Alejandro Freixes
Nov 14, 2011

Amgen cuts LDL cholesterol by two-thirds

Amgen is seeking to revolutionize LDL cholesterol treatment by blocking a protein called PCSK9. Early trials indicate the AMG145 treatment was able to reduce LDL levels by 64 percent compared to the placebo injection. Presented at the American Heart Assocation in Orlando, the study involved both men and women 18 to 45 years of age. Other biotech companies like Regeneron and Sanofi have already claimed the vanguard position in developing successful means of blocking PCSK9.


SOURCE: Reuters